>
World's Cancer Patients Face Inequities in Access to Newer Drugs
05.10.07, 12:00 AM ET
THURSDAY, May 10 (HealthDay News) -- Patients' access to new and better cancer drugs varies widely depending on which country they live in, a new Swedish study says.
Researchers analyzed data on access to 67 innovative cancer drugs in 25 countries, including Australia, Canada, Japan, New Zealand, South Africa, the United States, and 19 European nations.
The study found that Austria, France, Switzerland and the United States are the leaders in the use of new cancer drugs, while New Zealand, Poland, the Czech Republic, South Africa and the United Kingdom are the slowest to use new cancer drugs.
The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found. For example, the use of bevacizumab for colorectal cancer and erlotinib for lung cancer in the United States was 10 times higher than the European average.
The use of cetuximab for colorectal cancer was highest in France and the United States and lowest in Finland. The use of pemetrexed for lung cancer was also high in France and the United States and low in Canada, the Czech Republic, New Zealand, Poland, and the United Kingdom.
"Progress in medical treatments has meant that over half of the patients diagnosed with cancer will now be 'cured' or die from other causes. However, these benefits are only realized once the drugs get to the patients," study co-author Dr. Bengt Jonsson, director of the Center for Health Economics at the Stockholm School of Economics, said in a prepared statement.
"Our report highlights that in many countries new drugs are not reaching patients quickly enough and that this is having an adverse impact on patient survival. Where you live can determine whether you receive the best available treatment or not. To some extent, this is determined by economic factors, but much of the variation between countries remains unexplained," Jonsson said.
"In the U.S., we have found that the survival of cancer patients is significantly related to the introduction of new oncology drugs," he noted. The study also found "differences in access (to new cancer drugs) reflected in patient outcome in the five major European countries: France, Germany, Italy, Spain and the U.K."
The study findings, by researchers from the Karolinska Institute in Stockholm and the Center for Health Economics at the Stockholm School of Economics, are published in the May 10 issue of Annals of Oncology.
本人认领此文. 如在48小时内未能提交译文, 其他战友自由认领.
译文６９２字．
World's Cancer Patients Face Inequities in Access to Newer Drugs
05.10.07, 12:00 AM ET
世界癌症患者应用新药面临不平等
THURSDAY, May 10 (HealthDay News) -- Patients' access to new and better cancer drugs varies widely depending on which country they live in, a new Swedish study says.
Researchers analyzed data on access to 67 innovative cancer drugs in 25 countries, including Australia, Canada, Japan, New Zealand, South Africa, the United States, and 19 European nations.
5月10日，星期四，（每日健康新闻）—一项新的瑞典研究称，癌症患者能否得到更新更好的抗癌药物治疗，根据其所在国不同而有很大差异。
研究人员分析了67种新型抗癌药物在25个国家的应用情况资料，这些国家包括澳大利亚、加拿大、日本、新西兰、南非、美国，以及19个欧洲国家。
The study found that Austria, France, Switzerland and the United States are the leaders in the use of new cancer drugs, while New Zealand, Poland, the Czech Republic, South Africa and the United Kingdom are the slowest to use new cancer drugs.
研究发现，在应用新型抗癌药物方面，澳大利亚、法国、瑞士、美国处于领先地位，而新西兰、波兰、捷克、南非及英国最为滞后。
The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found. For example, the use of bevacizumab for colorectal cancer and erlotinib for lung cancer in the United States was 10 times higher than the European average.
差别最为悬殊的是新型抗结肠直肠癌及肺癌药物的应用，这些药物包括贝伐单抗、西妥昔单抗、埃罗替尼及培美曲塞。例如，美国应用贝伐单抗治疗直肠结肠癌以及埃罗替尼治疗肺癌是欧洲平均水平的10倍。
The use of cetuximab for colorectal cancer was highest in France and the United States and lowest in Finland. The use of pemetrexed for lung cancer was also high in France and the United States and low in Canada, the Czech Republic, New Zealand, Poland, and the United Kingdom.
法国及美国应用西妥昔单抗治疗直肠结肠癌最多，而芬兰最低。培美曲塞治疗肺癌也是法国及美国最多，加拿大、捷克、新西兰、波兰及英国较低。
"Progress in medical treatments has meant that over half of the patients diagnosed with cancer will now be 'cured' or die from other causes. However, these benefits are only realized once the drugs get to the patients," study co-author Dr. Bengt Jonsson, director of the Center for Health Economics at the Stockholm School of Economics, said in a prepared statement.
在一项声明中，作者斯德哥尔摩经济学院卫生经济学中心主管Bengt Jonsson,称，药物治疗的进步意味着一半以上的癌症患者现在可以 “治愈”，或死于其他原因。但是，只有患者能得到这些药物治疗，才能达到这种效果。
"Our report highlights that in many countries new drugs are not reaching patients quickly enough and that this is having an adverse impact on patient survival. Where you live can determine whether you receive the best available treatment or not. To some extent, this is determined by economic factors, but much of the variation between countries remains unexplained," Jonsson said.
他说：“我们的报告强调，在很多国家，癌症患者不能够尽快得到新型抗癌药物治疗，这不利于患者存活。患者能否得到最好的治疗取决于他的所在国。在某种程度上，这由经济因素决定，但国家之间的很多变量还有待解释。”
"In the U.S., we have found that the survival of cancer patients is significantly related to the introduction of new oncology drugs," he noted. The study also found "differences in access (to new cancer drugs) reflected in patient outcome in the five major European countries: France, Germany, Italy, Spain and the U.K."
他强调说：“在美国，我们发现癌症患者的生存率与应用新的抗癌药物显著相关。”研究还发现，“在五个主要欧洲国家即法国、德国、意大利、西班牙及英国，可以从预后看出患者应用新型抗癌药物情况不同。”
The study findings, by researchers from the Karolinska Institute in Stockholm and the Center for Health Economics at the Stockholm School of Economics, are published in the May 10 issue of Annals of Oncology.
这一研究由斯德哥尔摩Karolinska协会、斯德哥尔摩经济学院卫生经济学中心完成，发表在《肿瘤学年鉴》5月10日号。
编译
癌症患者应用新型抗癌药物各国不等
5月10日，星期四，（每日健康新闻）—发于《肿瘤学年鉴》5月10日刊中的一项研究称，癌症患者能否得到更新更好的抗癌药物治疗，根据其所在国不同而有很大差异。
这一研究由斯德哥尔摩Karolinska协会、斯德哥尔摩经济学院卫生经济学中心完成。研究人员分析了67种新型抗癌药物在25个国家的应用情况资料，这些国家包括澳大利亚、加拿大、日本、新西兰、南非、美国，以及19个欧洲国家。
结果表明，在应用新型抗癌药物方面，澳大利亚、法国、瑞士、美国处于领先地位，而新西兰、波兰、捷克、南非及英国最为滞后。
差别最为悬殊的是新型抗结肠直肠癌及肺癌药物的应用，这些药物包括贝伐单抗、西妥昔单抗、埃罗替尼及培美曲塞。例如，美国应用贝伐单抗治疗直肠结肠癌以及埃罗替尼治疗肺癌是欧洲平均水平的10倍。
研究发现，在美国们发现癌症患者的生存率与应用新的抗癌药物显著相关。而在五个主要欧洲国家即法国、德国、意大利、西班牙及英国，可以从预后看出患者应用新型抗癌药物情况不同。
作者斯德哥尔摩经济学院卫生经济学中心主管Bengt Jonsson,称，药物治疗的进步意味着一半以上的癌症患者现在可以 “治愈”，但是只有患者能应用这些药物，才能达到这种效果。在很多国家，癌症患者不能够尽快得到新型抗癌药物治疗，这不利于患者存活。患者能否得到最好的治疗取决于他的所在国。在某种程度上，这由经济因素决定，但国家之间的很多变量还有待解释。
